Denali Therapeutics (DNLI) Invested Capital (2017 - 2025)
Historic Invested Capital for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $931.8 million.
- Denali Therapeutics' Invested Capital fell 2962.97% to $931.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $931.8 million, marking a year-over-year decrease of 2962.97%. This contributed to the annual value of $1.2 billion for FY2024, which is 2018.24% up from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Invested Capital is $931.8 million, which was down 2962.97% from $1.0 billion recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Invested Capital peaked at $1.5 billion during Q1 2024, and registered a low of $812.7 million during Q3 2022.
- Moreover, its 5-year median value for Invested Capital was $1.0 billion (2022), whereas its average is $1.1 billion.
- In the last 5 years, Denali Therapeutics' Invested Capital soared by 11361.52% in 2021 and then plummeted by 2962.97% in 2025.
- Over the past 5 years, Denali Therapeutics' Invested Capital (Quarter) stood at $962.3 million in 2021, then grew by 8.78% to $1.0 billion in 2022, then dropped by 1.52% to $1.0 billion in 2023, then grew by 20.18% to $1.2 billion in 2024, then dropped by 24.79% to $931.8 million in 2025.
- Its Invested Capital stands at $931.8 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.